CR20220465A - Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos - Google Patents
Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismosInfo
- Publication number
- CR20220465A CR20220465A CR20220465A CR20220465A CR20220465A CR 20220465 A CR20220465 A CR 20220465A CR 20220465 A CR20220465 A CR 20220465A CR 20220465 A CR20220465 A CR 20220465A CR 20220465 A CR20220465 A CR 20220465A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- formulations
- same
- human anti
- tslp antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978201P | 2020-02-18 | 2020-02-18 | |
| PCT/US2021/018561 WO2021168100A1 (en) | 2020-02-18 | 2021-02-18 | Formulations of human anti-tslp antibodies and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220465A true CR20220465A (es) | 2023-03-30 |
Family
ID=74860588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220465A CR20220465A (es) | 2020-02-18 | 2021-02-18 | Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230081261A1 (enExample) |
| EP (1) | EP4106811A1 (enExample) |
| JP (1) | JP2023513833A (enExample) |
| KR (1) | KR20220143699A (enExample) |
| CN (1) | CN115151276A (enExample) |
| AR (1) | AR121368A1 (enExample) |
| AU (1) | AU2021221998A1 (enExample) |
| CA (1) | CA3167975A1 (enExample) |
| CL (1) | CL2022002251A1 (enExample) |
| CO (1) | CO2022013251A2 (enExample) |
| CR (1) | CR20220465A (enExample) |
| IL (1) | IL295511A (enExample) |
| JO (1) | JOP20220193A1 (enExample) |
| MX (1) | MX2022010120A (enExample) |
| PE (1) | PE20230115A1 (enExample) |
| PH (1) | PH12022552132A1 (enExample) |
| TW (1) | TW202144004A (enExample) |
| UY (1) | UY39089A (enExample) |
| WO (1) | WO2021168100A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4145105A1 (de) * | 2021-09-06 | 2023-03-08 | Anacyte Laboratories GmbH | Lösung für die asservierung von zellen |
| CN118215681A (zh) * | 2021-09-18 | 2024-06-18 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1抗原结合片段的组合物及其用途 |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202426485A (zh) * | 2022-10-26 | 2024-07-01 | 美商安進公司 | 抗ｔｓｌｐ抗體組成物及其用途 |
| WO2024146630A1 (zh) * | 2023-01-06 | 2024-07-11 | 江苏恒瑞医药股份有限公司 | 一种tslp抗体治疗哮喘的方法 |
| WO2024238877A1 (en) * | 2023-05-18 | 2024-11-21 | Medimmune, Llc | Treatment of corticosteroid dependent asthma with anti-tslp antibody |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| EP3594356A1 (en) | 2009-11-04 | 2020-01-15 | Merck Sharp & Dohme Corp. | Engineered anti-tslp antibody |
| SI2523688T1 (en) * | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| CN107428828A (zh) | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| EA038332B1 (ru) | 2015-09-09 | 2021-08-10 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
| EP3609917A1 (en) * | 2017-04-12 | 2020-02-19 | Amgen Inc. | Treatment of asthma with anti-tslp antibody |
| MA48461A (fr) * | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
| IL319987A (en) | 2017-11-10 | 2025-06-01 | Amgen Inc | Plungers for drug delivery devices |
| WO2019178151A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| MA53913A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament |
| JP7719714B2 (ja) | 2018-10-15 | 2025-08-06 | アムジエン・インコーポレーテツド | ダンピング機構を有する薬物送達装置 |
-
2021
- 2021-02-18 MX MX2022010120A patent/MX2022010120A/es unknown
- 2021-02-18 EP EP21710848.9A patent/EP4106811A1/en active Pending
- 2021-02-18 WO PCT/US2021/018561 patent/WO2021168100A1/en not_active Ceased
- 2021-02-18 UY UY0001039089A patent/UY39089A/es unknown
- 2021-02-18 KR KR1020227031575A patent/KR20220143699A/ko active Pending
- 2021-02-18 AU AU2021221998A patent/AU2021221998A1/en active Pending
- 2021-02-18 US US17/760,470 patent/US20230081261A1/en active Pending
- 2021-02-18 PE PE2022001777A patent/PE20230115A1/es unknown
- 2021-02-18 CA CA3167975A patent/CA3167975A1/en active Pending
- 2021-02-18 AR ARP210100423A patent/AR121368A1/es unknown
- 2021-02-18 IL IL295511A patent/IL295511A/en unknown
- 2021-02-18 CR CR20220465A patent/CR20220465A/es unknown
- 2021-02-18 JP JP2022549318A patent/JP2023513833A/ja active Pending
- 2021-02-18 PH PH1/2022/552132A patent/PH12022552132A1/en unknown
- 2021-02-18 JO JOP/2022/0193A patent/JOP20220193A1/ar unknown
- 2021-02-18 TW TW110105518A patent/TW202144004A/zh unknown
- 2021-02-18 CN CN202180015035.0A patent/CN115151276A/zh active Pending
-
2022
- 2022-08-18 CL CL2022002251A patent/CL2022002251A1/es unknown
- 2022-09-16 CO CONC2022/0013251A patent/CO2022013251A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220143699A (ko) | 2022-10-25 |
| PH12022552132A1 (en) | 2024-01-29 |
| MX2022010120A (es) | 2022-09-05 |
| PE20230115A1 (es) | 2023-01-27 |
| AR121368A1 (es) | 2022-06-01 |
| CA3167975A1 (en) | 2021-08-26 |
| EP4106811A1 (en) | 2022-12-28 |
| UY39089A (es) | 2021-08-31 |
| AU2021221998A1 (en) | 2022-09-15 |
| WO2021168100A1 (en) | 2021-08-26 |
| IL295511A (en) | 2022-10-01 |
| CL2022002251A1 (es) | 2023-04-14 |
| CN115151276A (zh) | 2022-10-04 |
| CO2022013251A2 (es) | 2022-12-20 |
| JOP20220193A1 (ar) | 2023-01-30 |
| BR112022016456A2 (pt) | 2022-10-04 |
| US20230081261A1 (en) | 2023-03-16 |
| TW202144004A (zh) | 2021-12-01 |
| JP2023513833A (ja) | 2023-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552132A1 (en) | Formulations of human anti-tslp antibodies and methods of using the same | |
| SA521430342B1 (ar) | تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري | |
| TW200602078A (en) | Uses of anti-CTLA-4 antibodies | |
| TW200618811A (en) | Antibody formulations | |
| JOP20220204B1 (ar) | الأجسام المضادة لـ cd19 البشرية | |
| AU2018274216A1 (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
| IN2012DN00313A (enExample) | ||
| UA85993C2 (ru) | Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего | |
| HRP20020787B1 (hr) | Postupak liječenja upotrebom kompleksa ligand-imunogen | |
| MX2021015651A (es) | Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap). | |
| EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
| TNSN08511A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| EA200401522A1 (ru) | Противотуберкулёзный препарат: композиции и способы | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| MX2022005249A (es) | Anticuerpos anti-cd45 y conjugados de los mismos. | |
| AR077611A1 (es) | Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso. | |
| MX2022011101A (es) | Formulaciones de anticuerpos anti protofibrillas beta amiloide de alta concentracion y metodos de uso de las mismas. | |
| WO2024011189A3 (en) | Methods of treating disease using anti-il1rap antibodies and antibody drug conjugates | |
| MX2025009383A (es) | Anticuerpos anti antigeno de membrana especifico de prostata (psma), conjugados y metodos de uso | |
| MX2025009090A (es) | Composiciones y métodos para tratar la enfermedad hemolítica del feto y del recién nacido | |
| ZA202209925B (en) | Compositions and methods for treating pompe disease | |
| BR112022022620A2 (pt) | Formulações de anticorpos anti-il-33 | |
| MX2022014455A (es) | Formulacion de anticuerpo anti-clever-1 estable. | |
| WO2021257695A8 (en) | Methods and compositions related to neutralizing antibodies against human coronavirus | |
| MX2024014811A (es) | Composiciones de menaquinol pegilado y metodos de tratamiento |